Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL561964 | 1.00 | SOAT1 (0.41) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL515770 | 0.98 | SOAT1 (0.38) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL250912 | 0.98 | SOAT1 (0.42) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL562372 | 0.98 | SOAT1 (0.38) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4151443 | 0.98 | SOAT1 (0.42) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL154713 | 0.95 | SOAT1 (0.39) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31119920 | 0.93 | FAAH (0.39) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL561987 | 0.91 | KDM4E (0.35) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL691540 | 0.91 | KDM4E (0.35) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL232206 | 0.88 | KDM4E (0.36) | SOAT1TP53CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299383-B1 | SPECIFIC MODIFICATION OF ANTIBODY WITH IGG-BINDING PEPTIDE | UNIV KAGOSHIMA (JP) | 2025-12-03 | — | — | EP | claimed |
| EP-3981826-B1 | SILANE COUPLING AGENT COMPOSITION COMPRISING SILANE COMPOUND AND PROTEIN MODIFYING AGENT, AND RUBBER COMPOSITION COMPRISING THE SAME | ENEOS MAT CORPORATION (JP) | 2025-10-01 | — | — | EP | claimed |
| EP-3470418-B1 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IGG-BINDING PEPTIDE | UNIV KAGOSHIMA (JP) | 2024-07-31 | — | — | EP | claimed |
| EP-1133318-B1 | SUPRAMOLECULAR COMPLEXES CONTAINING THERAPEUTIC AGENTS | CALIFORNIA INST OF TECHN (US) | 2007-03-14 | — | — | EP | claimed |
| US-20060223156-A1 | Controlled dissolution crosslinked protein in crystals | ALTHEA TECHNOLOGIES, INC. | 2006-10-05 | — | — | US | claimed |
| EP-0832201-B1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | UNIV ARIZONA (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1131281-B1 | DERIVATISATION OF SUPPORT SURFACES | DEUTSCHES KREBSFORSCH (DE) | 2005-07-27 | — | — | EP | claimed |
| US-6905724-B1 | Derivatization of support surfaces | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2005-06-14 | — | — | US | claimed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | claimed |
| WO-2002061045-A2 | SIMPLIFIED METHOD FOR INDEXING AND DETERMINING THE RELATIVE CONCENTRATION OF EXPRESSED MESSENGER RNAS | DIGITAL GENE TECHNOLOGIES, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-20020012922-A1 | Simplified method for indexing and determining the relative concentration of expressed messenger RNAs | NEUROME, INC. | 2002-01-31 | — | — | US | claimed |
| WO-2001083696-A2 | METHODS FOR RAPID ISOLATION AND SEQUENCE DETERMINATION OF GENE-SPECIFIC SEQUENCES | DIGITAL GENE TECH INC (US) | 2001-11-08 | — | — | WO | claimed |
| EP-1131281-A2 | DERIVATISATION OF SUPPORT SURFACES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-09-12 | — | — | EP | claimed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | claimed |
| US-6093541-A | WITH METAL PRESENTATION SURFACE HAVING IMMOBILIZED COMPLEX OF TETHERING MOLECULE AND DIGESTION MOLECULE; FOR RAPID AND EFFICIENT ANALYSIS OF BIOMOLECULES USING MATRIX-ASSISTED LASER DESORPTION/IONIZATION TECHNIQUE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 2000-07-25 | — | — | US | claimed |
| WO-2000029373-A2 | DERIVATISATION OF SUPPORT SURFACES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2000-05-25 | — | — | WO | claimed |
| US-6004770-A | MASS SPECTROMETRY SAMPLE PRESENTATION APPARATUSES DERIVATIZED WITH COMPLEXES INCLUDING AT LEAST ONE MOLECULE WHICH MODIFIES A BIOMOLECULE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 1999-12-21 | — | — | US | claimed |
| EP-0184710-A2 | Magnetic microspheres | BAYER AG (DE) | 1986-06-18 | — | — | EP | claimed |
| US-20250296984-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2025-09-25 | — | — | US | disclosed |
| EP-4472663-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2024-12-11 | — | — | EP | disclosed |
| US-20240307543-A1 | One-Step Processing of Hydrogels for Mechanically Robust and Chemically Desired Features | UNIV TEXAS (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240199724-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2024-06-20 | — | — | US | disclosed |
| EP-2961395-B1 | TARGETED NANOPARTICLES | CALIFORNIA INST OF TECHN (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023190243-A1 | METHOD FOR PREPARING SUPRAMOLECULAR HYDROGEL, AND APPLICATION AS BIOMATERIAL | デンカ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-4232057-A2 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023144392-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022162192-A2 | THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF | THELPER AS (NO) | 2022-08-04 | — | — | WO | disclosed |
| EP-2323628-B1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INST OF TECHN (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11236131-B2 | Re-directed immunotherapy | THE UNIVERSITY OF BIRMINGHAM (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20210283258-A1 | TARGETED NANOPARTICLES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2021-09-16 | — | — | US | disclosed |
| EP-2819701-B2 | IMMUNOTHERAPEUTIC MOLECULES AND USES | UNIV BIRMINGHAM (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-2773427-B1 | AN ANDROGEN RECEPTOR OR ESTRADIOL RECEPTOR INHIBITOR FOR USE IN THE TREATMENT OF A CANCEROUS OR NON-CANCEROUS CONDITION | VALIRX PLC (GB) | 2021-01-13 | — | — | EP | disclosed |
| EP-3714903-A1 | NANOPARTICLES STABILIZED WITH NIITROPHENYLBORONIC ACID COMPOSITIONS | California Institute of Technology (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3513812-B1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | CALIFORNIA INST OF TECHN (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20190314520-A1 | Carrier Nanoparticles And Related Compositions, Methods And Systems | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-10-17 | — | — | US | disclosed |
| US-20190270779-A1 | Re-Directed Immunotherapy | THE UNIVERSITY OF BIRMINGHAM (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10400008-B2 | Modulators of the SRC-kinase activity for preventing or treating metastatic cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-1492554-B1 | SPHERICAL PROTEIN PARTICLES | ALTHEA TECH INC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3513812-A1 | NANOPARTICLES STABILIZED WITH NIITROPHENYLBORONIC ACID COMPOSITIONS | California Institute of Technology (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10342879-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-07-09 | — | — | US | disclosed |
| US-10287321-B2 | Re-directed immunotherapy | THE UNIVERSITY OF BIRMINGHAM (GB) | 2019-05-14 | — | — | US | disclosed |
| EP-2961788-B1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | CALIFORNIA INST OF TECHN (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190117773-A1 | Targeted Nanoparticles | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-04-25 | — | — | US | disclosed |
| EP-3246334-B1 | IMMUNOTHERAPY | UNIV BIRMINGHAM (GB) | 2019-02-20 | — | — | EP | disclosed |
| US-20190000990-A1 | Carrier Nanoparticles And Related Compositions, Methods And Systems | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2019-01-03 | — | — | US | disclosed |
| EP-3138581-B1 | RE-DIRECTED IMMUNOTHERAPY | UNIV BIRMINGHAM (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-10166291-B2 | Targeted nanoparticles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-01-01 | — | — | US | disclosed |
| US-10155051-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-12-18 | — | — | US | disclosed |
| US-10106621-B2 | Immunotherapeutic molecules and uses | THE UNIVERSITY OF BIRMINGHAM (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20180273585-A1 | Medical Use | VALIRX PLC (GB) | 2018-09-27 | — | — | US | disclosed |
| EP-2819701-B1 | IMMUNOTHERAPEUTIC MOLECULES AND USES | UNIV BIRMINGHAM (GB) | 2018-07-25 | — | — | EP | disclosed |
| US-10023612-B2 | Method of treating endometriosis | VALIRX PLC (GB) | 2018-07-17 | — | — | US | disclosed |
| US-20180169265-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-06-21 | — | — | US | disclosed |
| US-20180105599-A1 | IMMUNOTHERAPEUTIC MOLECULES AND USES | THE UNIVERSITY OF BIRMINGHAM (GB) | 2018-04-19 | — | — | US | disclosed |
| US-9913911-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20180030207-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-02-01 | — | — | US | disclosed |
| EP-3246334-A1 | IMMUNOTHERAPY | The University Of Birmingham (GB) | 2017-11-22 | — | — | EP | disclosed |
| US-9822180-B2 | Immunotherapeutic molecules and uses | THE UNIVERSITY OF BIRMINGHAM (GB) | 2017-11-21 | — | — | US | disclosed |
| US-20170296665-A1 | TARGETED NANOPARTICLES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-10-19 | — | — | US | disclosed |
| EP-3016969-B1 | IMMUNOTHERAPY | UNIV BIRMINGHAM (GB) | 2017-08-30 | — | — | EP | disclosed |
| US-9650445-B2 | Immunotherapeutic molecules and uses | THE UNIVERSITY OF BIRMINGHAM (GB) | 2017-05-16 | — | — | US | disclosed |
| US-9610355-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170080099-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-03-23 | — | — | US | disclosed |
| EP-3138581-A1 | RE-DIRECTED IMMUNOTHERAPY | The University of Birmingham (GB) | 2017-03-08 | — | — | EP | disclosed |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-02-23 | — | — | US | disclosed |
| EP-2686020-B1 | RE-DIRECTED IMMUNOTHERAPY | UNIV BIRMINGHAM (GB) | 2017-02-22 | — | — | EP | disclosed |
| EP-2198880-B1 | Compositions containing lipase, protease and amylase for treating pancreatic insufficiency | LILLY CO ELI (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9468681-B2 | Targeted nanoparticles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9446149-B2 | Nanoparticles stabilized with nitrophenylboronic acid compositions | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160228566-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-08-11 | — | — | US | disclosed |
| US-9402916-B2 | Re-directed immunotherapy | THE UNIVERSITY OF BIRMINGHAM (GB) | 2016-08-02 | — | — | US | disclosed |
| US-20160206726-A1 | IMMUNOTHERAPY | THE UNIVERSITY OF BIRMINGHAM (GB) | 2016-07-21 | — | — | US | disclosed |
| US-9358282-B2 | Re-directed immunotherapy | THE UNIVERSITY OF BIRMINGHAM (GB) | 2016-06-07 | — | — | US | disclosed |
| EP-3016969-A1 | IMMUNOTHERAPY | The University Of Birmingham (GB) | 2016-05-11 | — | — | EP | disclosed |
| US-9334367-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160106862-A1 | Re-Directed Immunotherapy | THE UNIVERSITY OF BIRMINGHAM (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9310379-B2 | Methods of crystallizing antibodies | AJINOMOTO ALTHEA, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20160068568-A1 | MODULATORS OF THE SRC-KINASE ACTIVITY FOR PREVENTING OR TREATING METASTATIC CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| EP-2991662-A2 | MODULATORS OF THE SRC-KINASE ACTIVITY FOR PREVENTING OR TREATING METASTATIC CANCER | Cancer Research Technology Ltd (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20160039942-A1 | IMMUNOTHERAPEUTIC MOLECULES AND USES | THE UNIVERSITY OF BIRMINGHAM (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160000934-A1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| US-9186327-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150322207-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-11-12 | — | — | US | disclosed |
| US-20150297745-A1 | Agents and Methods | UNIVERSITY OF BIRMINGHAM (GB) | 2015-10-22 | — | — | US | disclosed |
| US-9132097-B2 | Nanoparticles stabilized with nitrophenylboronic acid compositions | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150250868-A1 | Re-Directed Immunotherapy | THE UNIVERSITY OF BIRMINGHAM (GB) | 2015-09-10 | — | — | US | disclosed |
| EP-2897642-A2 | AGENTS AND METHODS | The University Of Birmingham (GB) | 2015-07-29 | — | — | EP | disclosed |
| CN-104812413-A | Agents and methods | UNIV BIRMINGHAM | 2015-07-29 | — | — | CN | disclosed |
| US-20150183875-A1 | IMMUNOTHERAPEUTIC MOLECULES AND USES | UNIVERSITY OF BIRMINGHAM (GB) | 2015-07-02 | — | — | US | disclosed |
| US-8968714-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031832-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-01-29 | — | — | US | disclosed |
| CN-104321081-A | Immunotherapeutic molecules and uses | UNIV BIRMINGHAM | 2015-01-28 | — | — | CN | disclosed |
| WO-2015001361-A1 | IMMUNOTHERAPY | THE UNIVERSITY OF BIRMINGHAM (GB) | 2015-01-08 | — | — | WO | disclosed |
| EP-2819701-A1 | IMMUNOTHERAPEUTIC MOLECULES AND USES | The University Of Birmingham (GB) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014177868-A2 | MEDICAL USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-11-06 | — | — | WO | disclosed |
| US-20140322306-A1 | Medical Use | VALIRX PLC (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2773427-A2 | MEDICAL USE | Valirx Plc. (GB) | 2014-09-10 | — | — | EP | disclosed |
| US-20140249202-A1 | TARGETED NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-04 | — | — | US | disclosed |
| US-20140249203-A1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-04 | — | — | US | disclosed |
| US-8746999-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-06-10 | — | — | US | disclosed |
| WO-2014045022-A2 | AGENTS AND METHODS | THE UNIVERSITY OF BIRMINGHAM (GB) | 2014-03-27 | — | — | WO | disclosed |
| EP-2686020-A1 | RE-DIRECTED IMMUNOTHERAPY | The University of Birmingham (GB) | 2014-01-22 | — | — | EP | disclosed |
| US-20140004081-A1 | Re-Directed Immunotherapy | THE UNIVERSITY OF BIRMINGHAM (GB) | 2014-01-02 | — | — | US | disclosed |
| US-8557292-B2 | Carrier nanoparticles and related compositions, methods and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2013128194-A1 | IMMUNOTHERAPEUTIC MOLECULES AND USES | THE UNIVERSITY OF BIRMINGHAM (GB) | 2013-09-06 | — | — | WO | disclosed |
| US-20130211012-A1 | Carrier Nanoparticles and Related Compositions, Methods and Systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130209448-A1 | Carrier Nanoparticles and Related Compositions, Methods and Systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130197210-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130184453-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013064830-A2 | MEDICAL USE | VALIRX PLC (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-1682168-B1 | NON-PANCREATIC PROTEASES FOR CONTROLLING PLASMA CHOLECYSTOKININ (CCK) CONCENTRATION AND FOR TREATING PAIN | LILLY CO ELI (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-1764112-B1 | Method for preparing linear cyclodextrin copolymers | CALIFORNIA INST OF TECHN (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20120282464-A1 | Spherical Protein Particles and Methods of Making and Using Them | ALTHEA TECHNOLOGIES, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8277846-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-10-02 | — | — | US | disclosed |
| WO-2012123755-A1 | RE-DIRECTED IMMUNOTHERAPY | THE UNIVERSITY OF BIRMINGHAM (GB) | 2012-09-20 | — | — | WO | disclosed |
| US-20120172525-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8092833-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7998477-B2 | spherical nanocrystalline composite particles or crystalline SPPs; protein is an antibody or FV fragment; tumor antigens, cardiovascular disorders, respiratory system disorders, transplant rejection, anticarcinogenic agents, antiinflammatory agents, radioimmunotherapeutic agents | ALTHEA TECHNOLOGIES INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-07-28 | — | — | US | disclosed |
| US-7981694-B2 | Using microbeads comprising immobilized g-protein to identify guanine nucleotide-binding protein binding partners | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-19 | — | — | US | disclosed |
| US-7968123-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2011073692-A1 | PROTEINS, NUCLEIC ACID MOLECULES AND COMPOSITIONS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144190-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2325205-A2 | Crystals of whole antibodies and fragments thereof and methods for making and using them | Altus Pharmaceuticals Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110033946-A1 | DETECTION OF SHORT-CHAIN FATTY ACIDS IN BIOLOGICAL SAMPLES | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7872103-B2 | Modulating immune responses | CELLTECH R & D, LIMITED (GB) | 2011-01-18 | — | — | US | disclosed |
| EP-2267122-A1 | Controlled dissolution crosslinked protein crystals | Altus Pharmaceuticals Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2258724-A1 | Modulating immune responses using multimerized anti-CD83 antibodies | Celltech R & D, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7833525-B2 | Crystals of whole antibodies and fragments thereof and methods for making and using them | AJINOMOTO ALTHEA INC. | 2010-11-16 | — | — | US | disclosed |
| US-7807198-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100249380-A1 | Modulating Immune Responses | CELLTECH R&D LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| WO-2010105112-A1 | DETECTION OF SHORT-CHAIN FATTY ACIDS IN BIOLOGICAL SAMPLES | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-1572976-B1 | MODULATING IMMUNE RESPONSES | CELLTECH R & D INC (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100196344-A1 | COMPOSITIONS AND METHODS FOR TREATING PANCREATIC INSUFFICIENCY | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| EP-1809320-B1 | COMPOSITIONS CONTAINING LIPASE; PROTEASE AND AMYLASE FOR TREATING PANCREATIC INSUFFICIENCY | ALTUS PHARMACEUTICALS INC (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2198880-A1 | Compositions containing lipase, protease and amylase for treating pancreatic insufficiency | Altus Pharmaceuticals Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| US-7718169-B2 | Compositions and methods for treating pancreatic insufficiency | CYSTIC FIBROSIS FOUNDATIONS THERAPEUTICS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1261368-B1 | CROSSLINKED, NON-FUNGAL LIPASE-CONTAINING COMPOSITION AND METHODS OF USE THEREOF | ALTUS PHARMACEUTICALS INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-7700559-B2 | Gonadotropin releasing hormone analogues conjugates with steroid hormones | MEDICAL RESEARCH COUNCIL (GB) | 2010-04-20 | — | — | US | disclosed |
| US-7700740-B2 | Antibodies to CD83 | CELLTECH R & D, LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20100040556-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20100040592-A1 | LIPASE-CONTAINING COMPOSITION AND METHODS OF USE THEREOF | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-7651857-B2 | Methods for enhancing antigen presentation | THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST (GB) | 2010-01-26 | — | — | US | disclosed |
| EP-1667715-B1 | ANTIGEN DELIVERY SYSTEM | ROYAL VETERINARY COLLEGE (GB) | 2009-09-23 | — | — | EP | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20090093617-A1 | Crystals of whole antibodies and fragments thereof and methods for making and using them | ALTUS PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090060915-A1 | POLYPEPTIDE, VACCINE AND USE THEREOF | BIOINVENT INTERNATIONAL AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20080299122-A1 | Modulating immune responses | UCB SA (GB) | 2008-12-04 | — | — | US | disclosed |
| US-20080279954-A1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1985699-A1 | Controlled dissolution crosslinked protein crystals | Altus Pharmaceuticals Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1613357-B1 | GONADOTROPIN RELEASING HORMONE ANALOGUE CONJUGATES WITH STEROID HORMONES | MEDICAL RES COUNCIL (GB) | 2008-10-15 | — | — | EP | disclosed |
| CN-101223169-A | Pyrrolo [2, 3-b ] pyridine derivative protein kinase inhibitors | PLEXXIKON INC (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-101213210-A | Polypeptide, vaccine and use thereof | BIOINVENT INT AB (SE) | 2008-07-02 | — | — | CN | disclosed |
| US-7375096-B1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080095789-A1 | Vaccine | BIOLNVENT INTERNATIONAL AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1879919-A2 | POLYPEPTIDE, VACCINE AND USE THEREOF | BIOINVENT INTERNATIONAL AB (SE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1642136-A4 | METHOD OF ISOLATING A PROTEIN | PROTEOME SYSTEMS INTELLECTUAL (AU) | 2007-12-12 | — | — | EP | disclosed |
| CN-101048660-A | Homogeneous enzyme immunoassay for oral fluid | LIN ZHI INTERNAT INC (US) | 2007-10-03 | — | — | CN | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-7253265-B2 | Antibody and a method for producing an antibody that specifically binds to a full length amino acid sequence of human Delta-1 | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20070178541-A1 | Method of isolating a protein | PROTEOME SYSTEMS INTELLECTUAL PROPERTY PTY LTD (AU) | 2007-08-02 | — | — | US | disclosed |
| EP-1809320-A1 | COMPOSITIONS CONTAINING LIPASE; PROTEASE AND AMYLASE FOR TREATING PANCREATIC INSUFFICIENCY | Altus Pharmaceuticals Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| CN-1993141-A | Induction of immune response against Streptococcus pneumoniae polysaccharides | EPIMMUNE INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1801123-A2 | Crystals of whole antibodies and fragments thereof and methods for making and using them | Altus Pharmaceuticals Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142312-A1 | Antigen delivery system | ROYAL VETERINARY COLLEGE, THE (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1572976-A4 | MODULATING IMMUNE RESPONSES | CELLTECH R & D INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1093469-B1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INST OF TECHN (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1004669-B1 | NOVEL DIFFERENTIATION INHIBITOR | ASAHI CHEMICAL IND (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-7198918-B2 | Nucleic acid encoding a human serrate-1 polypeptide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1764112-A2 | Linear cyclodextrin copolymers | California Institute of Technology (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1133318-B1 | SUPRAMOLECULAR COMPLEXES CONTAINING THERAPEUTIC AGENTS | CALIFORNIA INST OF TECHN (US) | 2007-03-14 | — | — | EP | disclosed |
| CN-1921883-A | Vaccine comprising an angiomotin or a polynucleotide encoding an angiomotin and its use for the treatment of angiogenic-related disorders | BIOINVENT INT AB (SE) | 2007-02-28 | — | — | CN | disclosed |
| US-7179622-B2 | Method of suppressing differentiation by administering a human serrate-1 polypeptide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20070025952-A1 | Linear cyclodextrin copolymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-02-01 | — | — | US | disclosed |
| US-7166302-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-01-23 | — | — | US | disclosed |
| US-7141379-B2 | Method of suppressing differentiation by administering a human serrate-1 polypeptide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2006-11-28 | — | — | US | disclosed |
| CN-1867356-A | Antigen delivery system | ROYAL VETERINARY COLLEGE (GB) | 2006-11-22 | — | — | CN | disclosed |
| US-7138276-B2 | Differentiation-suppressive polypeptide serrate-2 and methods of use | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2006-11-21 | — | — | US | disclosed |
| WO-2006117241-A2 | POLYPEPTIDE, VACCINE AND USE THEREOF | BIOINVENT INTERNATIONAL AB (SE) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247177-A1 | Gonadotropin releasing hormone analogues conjugates with steroid hormones | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2006-11-02 | — | — | US | disclosed |
| US-20060223156-A1 | Controlled dissolution crosslinked protein in crystals | ALTHEA TECHNOLOGIES, INC. | 2006-10-05 | — | — | US | disclosed |
| EP-1696950-A2 | VACCINE COMPRISING AN ANGIOMOTIN OR A POLYNUCLEOTIDE ENCODING AN ANGIOMOTIN AND ITS USE FOR THE TREATMENT OF ANGIOGENIC-RELATED DISORDERS | BIOINVENT INTERNATIONAL AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| US-20060182795-A1 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-08-17 | — | — | US | disclosed |
| US-7091192-B1 | Linear cyclodextrin copolymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060128587-A1 | Lipase-containing composition and methods of use thereof | ALTUS BIOLOGICS INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1667715-A2 | ANTIGEN DELIVERY SYSTEM | The Royal Veterinary College (GB) | 2006-06-14 | — | — | EP | disclosed |
| EP-0913404-B1 | DIFFERENTIATION INHIBITOR | ASAHI CHEMICAL IND (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20060121017-A1 | Compositions and methods for treating pancreatic insufficiency | ELI LILLY AND COMPANY | 2006-06-08 | — | — | US | disclosed |
| WO-2006044529-A1 | COMPOSITIONS CONTAINING LIPASE; PROTEASE AND AMYLASE FOR TREATING PANCREATIC INSUFFICIENCY | ALTUS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1642136-A1 | METHOD OF ISOLATING A PROTEIN | Proteome Systems Intellectual Property Pty Ltd. (AU) | 2006-04-05 | — | — | EP | disclosed |
| US-7022499-B2 | Nucleic acids encoding differentiation inhibitor delta 2 | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2006-04-04 | — | — | US | disclosed |
| US-7018609-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-03-28 | — | — | US | disclosed |
| EP-0861894-B1 | DIFFERENTIATION-SUPPRESSIVE POLYPEPTIDE | ASAHI CHEMICAL IND (JP) | 2006-03-08 | — | — | EP | disclosed |
| EP-1613357-A1 | GONADOTROPIN RELEASING HORMONE ANALOGUE CONJUGATES WITH STEROID HORMONES | Ardana Bioscience Limited (GB) | 2006-01-11 | — | — | EP | disclosed |
| EP-0832201-B1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | UNIV ARIZONA (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1572976-A2 | MODULATING IMMUNE RESPONSES | Celltech R & D, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050164408-A1 | Solid phase isolation of proteins, nucleic acids and other macromolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-28 | — | — | US | disclosed |
| US-20050164348-A1 | Method of suppressing differentiation by administering a human serrate-1 polypeptide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1131281-B1 | DERIVATISATION OF SUPPORT SURFACES | DEUTSCHES KREBSFORSCH (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005061538-A2 | VACCINE COMPRISING AN ANGIOMOTIN OR A POLYNUCLEOTIDE ENCODING AN ANGIOMOTIN AND ITS USES FOR THE TREATMENT OF ANGIOGENIC-RELATED DISORDERS | BIOINVENT INTERNATIONAL AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| US-20050130271-A1 | Method of suppressing differentiation by administering a human serrate-1 polypeptide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050130268-A1 | Method of suppressing differentiation by administering a human serrate-1 polypeptide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2005-06-16 | — | — | US | disclosed |
| US-6905724-B1 | Derivatization of support surfaces | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050100899-A1 | Analysing gene expression occurring in a microorganism before, during or after contact with or adhesion of the microorganism to an artificial lipid bilayer; micbiocides; antiinfective agents | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2005-05-12 | — | — | US | disclosed |
| US-6884789-B2 | Linear cyclodextrin copolymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-04-26 | — | — | US | disclosed |
| WO-2005014040-A2 | ANTIGEN DELIVERY SYSTEM | THE ROYAL VETERINARY COLLEGE (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005001480-A1 | METHOD OF ISOLATING A PROTEIN | PROTEOME SYSTEMS INTELLECTUAL PROPERTY PTY LTD (AU) | 2005-01-06 | — | — | WO | disclosed |
| EP-1492554-A2 | SPHERICAL PROTEIN PARTICLES AND METHODS OF MAKING AND USING THEM | Altus Biologics Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040241152-A1 | Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab | MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST, THE (GB) | 2004-12-02 | — | — | US | disclosed |
| US-20040219224-A1 | Spherical protein particles and methods for making and using them | AJINOMOTO ALTHEA INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004087215-A1 | GONADOTROPIN RELEASING HORMONE ANALOGUES CONJUGATES WITH STEROID HORMONES | ARDANA BIOSCIENCE LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
| US-20040185040-A1 | Modulating immune responses | CELLTECH R & D LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| WO-2004050124-A2 | CHIMAERIC MOLECULES | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050119-A1 | VACCINE AGAINST ENTEROPATHOGENIC AND ENTEROHAEMORRAGIC ESCHERICHIA COLI | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004048552-A2 | MODULATING IMMUNE RESPONSES | CELLTECH R & D, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040086516-A1 | Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling | MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST, THE (GB) | 2004-05-06 | — | — | US | disclosed |
| US-20040023324-A1 | Stem cell culture medium and culture method by using the same | JOHN P. ROBARTS RESEARCH INSTITUTE, THE (CA) | 2004-02-05 | — | — | US | disclosed |
| EP-1372709-A2 | INTIMINS FOR THE PREVENTION OR TREATMENT OF INFECTIONS: I | Imperial College Innovations Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6664098-B1 | Cellular differentiation and proliferation; ligands, membrane receptors; antigrowth agents; use of human Notch ligand, human Delta molecule, in development of drug candidates for differential regulation of undifferentiated cells | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-12-16 | — | — | US | disclosed |
| US-20030211127-A1 | Controlled dissolution crosslinked prote in crystals | ALTUS PHARMACEUTICALS INC. | 2003-11-13 | — | — | US | disclosed |
| US-6638741-B2 | Preferential antibody which prevents differentiation of cells | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-10-28 | — | — | US | disclosed |
| EP-1352082-A2 | SCREENING ASSAYS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| EP-1345617-A2 | METHODS OF MODULATING TOLL-RELATED RECEPTOR (TRR) SIGNALING | Synovis Limited (GB) | 2003-09-24 | — | — | EP | disclosed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | disclosed |
| EP-1312668-A1 | STEM CELL CULTURE MEDIUM AND CULTURE METHOD BY USING THE SAME | Asahi Kasei Kabushiki Kaisha (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-6566115-B1 | Protease conjugate for use in toiletries, laundry compositions, hard surface cleansing compositions and light duty cleaning compositions. | THE PROCTER & GAMBLE COMPANY | 2003-05-20 | — | — | US | disclosed |
| US-20030049788-A1 | Novel differentiation-inhibitor | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-03-13 | — | — | US | disclosed |
| US-20030032781-A1 | Differentiation-suppressive polypeptide | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-02-13 | — | — | US | disclosed |
| US-20030022368-A1 | Differentiation-suppressive polypeptide | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-01-30 | — | — | US | disclosed |
| US-20030017972-A1 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY AND INSERT THERAPEUTICS, INC | 2003-01-23 | — | — | US | disclosed |
| US-20030017144-A1 | Lipase-containing composition and methods of use thereof | ALTUS BIOLOGICS INC. | 2003-01-23 | — | — | US | disclosed |
| US-6509323-B1 | Cyclodextrin copolymers may be used as a delivery vehicle of various therapeutic agents | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-01-21 | — | — | US | disclosed |
| US-20030008818-A1 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY AND INSERT THERAPEUTICS, INC | 2003-01-09 | — | — | US | disclosed |
| WO-2003000014-A2 | SPHERICAL PROTEIN PARTICLES AND METHODS OF MAKING AND USING THEM | ALTUS BIOLOGICS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1261368-A2 | LIPASE-CONTAINING COMPOSITION AND METHODS OF USE THEREOF | Altus Biologics Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020151523-A1 | Linear cyclodextrin copolymers | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2002-10-17 | — | — | US | disclosed |
| WO-2002079240-A2 | INTIMINS FOR THE PREVENTION OR TREATMENT OF INFECTIONS: I | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002079247-A2 | INTIMINS IN THE PREVENTION OR TREATMENT OF INFECTIONS:II | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| US-20020137156-A1 | CONTROLLED DISSOLUTION CROSSLINKED PROTEIN CRYSTALS | ALTUS PHARMACEUTICALS INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020136719-A1 | Crystals of whole antibodies and fragments thereof and methods for making and using them | AJINOMOTO ALTHEA INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020128197-A1 | Differentiation-suppressive polypeptide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002061045-A2 | SIMPLIFIED METHOD FOR INDEXING AND DETERMINING THE RELATIVE CONCENTRATION OF EXPRESSED MESSENGER RNAS | DIGITAL GENE TECHNOLOGIES, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002051430-A2 | METHODS OF MODULATING TOLL-RELATED RECEPTOR (TRR) SIGNALING | SYNOVIS LIMITED (GB) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002034952-A2 | SCREENING ASSAYS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002034770-A1 | IDENTIFICATION OF HLA-DR RESTRICTED HCV EPITOPES | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2002-05-02 | — | — | WO | disclosed |
| US-20020049306-A1 | Differentiation-suppressive polypeptide | ASAHI KASEI KABUSHIKI KAISHA | 2002-04-25 | — | — | US | disclosed |
| US-20020012922-A1 | Simplified method for indexing and determining the relative concentration of expressed messenger RNAs | NEUROME, INC. | 2002-01-31 | — | — | US | disclosed |
| US-6337387-B1 | A POLYPEPTIDE ENCODING A HUMAN NOTCH LIGAND MOLECULE; FOR SUPPRESSING DIFFERENTIATION OF UNDIFFERENTIATED CELLS AND DRUG DEVELOPMENT | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2002-01-08 | — | — | US | disclosed |
| US-20010046493-A1 | Lipase-containing composition and methods of use thereof | ALTUS PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | disclosed |
| US-6316266-B1 | PROVIDING MASS SPECTROMETRY SAMPLE PRESENTATION METAL SURFACE; CONTACTING COMPLEX WITH SURFACE TO FORM A SURFACE-BOUND COMPLEX; CONTACTING BIOMOLECULE WITH COMPLEX; APPLYING MATRIX ASSISTED LASER DESORPTION/IONIZATION MATRIX; DETERMINATION | ARIZONA STATE UNIVERSITY BOARD OF REGENTS | 2001-11-13 | — | — | US | disclosed |
| WO-2001083696-A2 | METHODS FOR RAPID ISOLATION AND SEQUENCE DETERMINATION OF GENE-SPECIFIC SEQUENCES | DIGITAL GENE TECH INC (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1133318-A1 | SUPRAMOLECULAR COMPLEXES CONTAINING THERAPEUTIC AGENTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6291210-B1 | POLYPEPTIDE; FOR SUPPRESSION DIFFERENTIATION OF UNDIFFERENTIATED CELLS; DIAGNOSTIC TOOL FOR DETECTING TUMOR CELLS; ANTIPROLIFERATIVE AGENTS | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-1131281-A2 | DERIVATISATION OF SUPPORT SURFACES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-09-12 | — | — | EP | disclosed |
| WO-2001062280-A2 | LIPASE-CONTAINING COMPOSITION AND METHODS OF USE THEREOF | ALTUS BIOLOGICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| EP-1005356-A4 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE INC (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | disclosed |
| EP-1093469-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | California Institute of Technology (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-1999064049-A9 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE INC (US) | 2001-01-18 | — | — | WO | disclosed |
| US-6093541-A | WITH METAL PRESENTATION SURFACE HAVING IMMOBILIZED COMPLEX OF TETHERING MOLECULE AND DIGESTION MOLECULE; FOR RAPID AND EFFICIENT ANALYSIS OF BIOMOLECULES USING MATRIX-ASSISTED LASER DESORPTION/IONIZATION TECHNIQUE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 2000-07-25 | — | — | US | disclosed |
| WO-2000033885-A1 | SUPRAMOLECULAR COMPLEXES CONTAINING THERAPEUTIC AGENTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-1005356-A1 | NOVEL ANTIBACTERIAL AGENTS | Advanced Medicine, Inc. (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-1004669-A1 | NOVEL DIFFERENTIATION INHIBITOR | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-05-31 | — | — | EP | disclosed |
| WO-2000029373-A2 | DERIVATISATION OF SUPPORT SURFACES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000001734-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-01-13 | — | — | WO | disclosed |
| US-6004770-A | MASS SPECTROMETRY SAMPLE PRESENTATION APPARATUSES DERIVATIZED WITH COMPLEXES INCLUDING AT LEAST ONE MOLECULE WHICH MODIFIES A BIOMOLECULE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 1999-12-21 | — | — | US | disclosed |
| WO-1999064049-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0913404-A1 | DIFFERENTIATION INHIBITOR | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1999-05-06 | — | — | EP | disclosed |
| EP-0832201-A4 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | UNIV ARIZONA (US) | 1998-11-25 | — | — | EP | disclosed |
| EP-0861894-A1 | DIFFERENTIATION-SUPPRESSIVE POLYPEPTIDE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5741715-A | FLUORESCENT POLARIZATION IMMUNOASSAY | ROCHE DIAGNOSTIC SYSTEMS, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0832201-A1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | ARIZONA BOARD OF REGENTS (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040888-A1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | ARIZONA BOARD OF REGENTS (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0745602-A1 | Quinidine immunoassay and reagents | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-04 | — | — | EP | disclosed |
| EP-0643305-A2 | Undercoating of solid phase surfaces and direct coating method | Ciba Corning Diagnostics Corp. (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0345723-B1 | Diethylenetriamine pentaacetic acid derivatives | NIHON MEDIPHYSICS CO LTD (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-5250702-A | Nonradioactive carriers for radioactive metal elements | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1993-10-05 | — | — | US | disclosed |
| US-5094950-A | Diagnostics | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1992-03-10 | — | — | US | disclosed |
| EP-0345723-A2 | Diethylenetriamine pentaacetic acid derivatives | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1989-12-13 | — | — | EP | disclosed |
| EP-0184710-A2 | Magnetic microspheres | BAYER AG (DE) | 1986-06-18 | — | — | EP | disclosed |
| US-4053590-A | BLOOD SUBSTITUTE, PLASMA EXPANDER | ALZA CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
| US-4001200-A | BLOOD SUBSTITUTE FOR CARRYING OXYGEN | ALZA CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-4001200-A | BLOOD SUBSTITUTE FOR CARRYING OXYGEN | ALZA CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-4001401-A | BLOOD SUBSTITUTE AND BLOOD PLASMA EXPANDER COMPRISING POLYHEMOGLOBIN | ALZA CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (38 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | GLA 88/4885SOAT1 1290/4885TP53 4299/4885 |
| US-20060247177-A1 | Gonadotropin releasing hormone analogues conjugates with steroid hormones | SHBG, GNRHR, LHCGR | GLA 1650/4885SOAT1 3171/4885TP53 2055/4885 |
| US-10342879-B2 | Carrier nanoparticles and related compositions, methods and systems | CA13, CA12, CLTA | GLA 1519/4885SOAT1 4213/4885TP53 211/4885 |
| US-20160228566-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CLTB, CLTA, SLC46A1 | GLA 2468/4885SOAT1 3757/4885TP53 214/4885 |
| US-20150322207-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CLTB, CLTA, SLC46A1 | GLA 2468/4885SOAT1 3757/4885TP53 214/4885 |
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | GLA 75/4885SOAT1 1528/4885TP53 4025/4885 |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | GLA 3485/4885SOAT1 3491/4885TP53 3684/4885 |
| US-20030008818-A1 | Compositions containing inclusion complexes | EXOSC5, EXOSC9, INTS6 | GLA 3612/4885SOAT1 3893/4885TP53 3339/4885 |
| US-20180030207-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | DDOST, SI, PDIA6 | GLA 1222/4885SOAT1 2503/4885TP53 1683/4885 |
| US-20190314520-A1 | Carrier Nanoparticles And Related Compositions, Methods And Systems | CA13, CA12, CLTA | GLA 1519/4885SOAT1 4213/4885TP53 211/4885 |
| US-20150031832-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CLTB, CLTA, SLC46A1 | GLA 2468/4885SOAT1 3757/4885TP53 214/4885 |
| US-20130209448-A1 | Carrier Nanoparticles and Related Compositions, Methods and Systems | CLTB, CLTA, SLC46A1 | GLA 2468/4885SOAT1 3757/4885TP53 214/4885 |
| US-20210283258-A1 | TARGETED NANOPARTICLES | CLTB, NBAS, NAPA | GLA 3041/4885SOAT1 3450/4885TP53 410/4885 |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | GLA 3485/4885SOAT1 3491/4885TP53 3684/4885 |
| US-10166291-B2 | Targeted nanoparticles | CLTB, NBAS, NAPA | GLA 3041/4885SOAT1 3450/4885TP53 410/4885 |
| US-20060182795-A1 | Compositions containing inclusion complexes | INTS6, EXOSC5, EXOSC9 | GLA 3502/4885SOAT1 4161/4885TP53 3516/4885 |
| US-20130211012-A1 | Carrier Nanoparticles and Related Compositions, Methods and Systems | CLTB, CLTA, SLC46A1 | GLA 2468/4885SOAT1 3757/4885TP53 214/4885 |
| US-20030017972-A1 | Complexing agents for compositions containing inclusion complexes | INTS6, EXOSC5, PCBP1 | GLA 3487/4885SOAT1 3356/4885TP53 3715/4885 |
| US-20070025952-A1 | Linear cyclodextrin copolymers | DDOST, SI, PDIA6 | GLA 1222/4885SOAT1 2503/4885TP53 1683/4885 |
| US-20190000990-A1 | Carrier Nanoparticles And Related Compositions, Methods And Systems | CA13, CA12, CLTA | GLA 1519/4885SOAT1 4213/4885TP53 211/4885 |
| US-20080279954-A1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | PICALM, IMMT, PAICS | GLA 4550/4885SOAT1 2473/4885TP53 1628/4885 |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | GLA 3649/4885SOAT1 3965/4885TP53 3314/4885 |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | INTS6, EXOSC5, PCBP1 | GLA 3485/4885SOAT1 3491/4885TP53 3684/4885 |
| US-10155051-B2 | Carrier nanoparticles and related compositions, methods and systems | CA13, CA12, CLTA | GLA 1519/4885SOAT1 4213/4885TP53 211/4885 |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | GLA 3649/4885SOAT1 3965/4885TP53 3314/4885 |
| US-20190117773-A1 | Targeted Nanoparticles | CLTB, NBAS, NAPA | GLA 3041/4885SOAT1 3450/4885TP53 410/4885 |
| US-20020151523-A1 | Linear cyclodextrin copolymers | DDOST, SI, PDIA6 | GLA 1222/4885SOAT1 2503/4885TP53 1683/4885 |
| US-20160000934-A1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | NCL, B3GNT2, NBAS | GLA 2581/4885SOAT1 1657/4885TP53 368/4885 |
| US-20170080099-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CA13, CA12, CLTA | GLA 1519/4885SOAT1 4213/4885TP53 211/4885 |
| US-20140249203-A1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | NCL, BPNT1, NCLN | GLA 2209/4885SOAT1 1899/4885TP53 297/4885 |
| US-20180169265-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CA13, CA12, CLTA | GLA 1519/4885SOAT1 4213/4885TP53 211/4885 |
| US-20140249202-A1 | TARGETED NANOPARTICLES | CLTB, CLTA, ACTB | GLA 2801/4885SOAT1 3377/4885TP53 214/4885 |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | GLA 3485/4885SOAT1 3491/4885TP53 3684/4885 |
| US-20100040556-A1 | CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CLTB, CLTA, SLC46A1 | GLA 2468/4885SOAT1 3757/4885TP53 214/4885 |
| US-20170296665-A1 | TARGETED NANOPARTICLES | CLTB, NBAS, NAPA | GLA 3041/4885SOAT1 3450/4885TP53 410/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | GLA 75/4885SOAT1 1528/4885TP53 4025/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | GLA 75/4885SOAT1 1528/4885TP53 4025/4885 |
| US-20110144190-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | PICALM, IMMT, PAICS | GLA 4550/4885SOAT1 2473/4885TP53 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.